You are here
SWOG Cancer Research
SWOG Cancer Research is a consortium that designs and conducts multidisciplinary clinical trials to improve the practice of medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors. The approximately 5,000 physician-researchers in the group’s network practice at more than 650 institutions nationwide, including 28 of the National Cancer Institute (NCI)-designated cancer centers, as well as cancer centers in almost a dozen other countries. Formerly the Southwest Oncology Group, SWOG is part of the NCI’s National Clinical Trials Network and is supported primarily through NCI research grant funding. The group is headquartered at the Oregon Health & Science University in Portland, Oregon, (503-494-5586), has an operations office in San Antonio, Texas, and has a statistical center in Seattle, Washington. Learn more at www.swog.org or follow us on Twitter (@SWOG).
National Cancer Institute
The National Cancer Institute (NCI) leads the National Cancer Program and the NIH effort to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. For more information about cancer, please visit the NCI website at www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
About the Foundation for the NIH
The Foundation for the National Institutes of Health creates and manages alliances with public and private institutions in support of the mission of the NIH, the world’s premier medical research agency. The Foundation, also known as the FNIH, works with its partners to accelerate key issues of scientific study and strategies against diseases and health concerns in the United States and across the globe. The FNIH organizes and administers research projects; supports education and training of new researchers; organizes educational events and symposia; and administers a series of funds supporting a wide range of health issues. Established by Congress in 1996, the FNIH is a not-for-profit 501(c)(3) charitable organization. For additional information about the FNIH, please visit www.fnih.org.
Friends of Cancer Research
Friends of Cancer Research develops groundbreaking partnerships and creates a more open dialogue among both public and private sectors and tears down the barriers that stand in the way of conquering cancer. By collaborating with premier academic research centers, professional societies, and other advocacy organizations, Friends is able to accelerate innovation. For more information, please visit: www.focr.org or follow us on Twitter (@CancerResrch).
Foundation Medicine® (NASDAQ: FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer. The company’s clinical assays, FoundationOneTM for solid tumors and FoundationOneTM Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify the molecular alterations in a patient’s tumor and match them with relevant targeted therapies and clinical trials. Foundation Medicine’s molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be the world’s largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. For more information, visit www.amgen.com and follow us on Twitter (@Amgen).
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.
MedImmune is the worldwide biologics research and development arm of AstraZeneca, a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialization of small molecule and biologic prescription medicines. MedImmune is pioneering innovative research and exploring novel pathways across key therapeutic areas, including respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines. The MedImmune headquarters is located in Gaithersburg, Md., one of AstraZeneca’s three global R&D centers. For more information, please visit www.medimmune.com.
Founded more than 35 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit www.gene.com.
Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time. For more information, please visit www.Pfizer.com.
Addario Lung Cancer Foundation
ALCF is committed to improving, extending and saving the lives of lung cancer patients worldwide. Through collaboration and partnership with the leaders in oncology, technology, science, medicine and philanthropy, we are raising awareness, providing extensive patient services and programs and funding innovative and timely research that will lead to better, more effective treatments.
We strongly believe personalized medicine is the gateway to success and we will power progress by involving patients, donors, clinicians, pharmaceutical and biotech companies, payers, government and public and private enterprise. For more information, visit lungcancerfoundation.org.
Lung Cancer Alliance
Lung Cancer Alliance (LCA) is committed to saving lives by helping people, accelerating research and advancing screening. LCA provides live, professional support, referral and information services to patients, their loved ones and those at risk for lung cancer; conducts national awareness campaigns; and advocates for multiple millions in public health dollars for lung cancer research. For more information, please visit http://www.lungcanceralliance.org.
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality-of-life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as providing community, support and education for all those affected by the disease. For more information, go to http://www.lungevity.org/
Free to Breathe
To double lung cancer survival by 2022, Free to Breathe focuses on accelerating research, helping patients understand treatment options and ensuring patients benefit from innovative therapies that save lives. To learn more and become involved in Free to Breathe’s vision to double lung cancer survival visit freetobreathe.org.
Lung Cancer Foundation of America
Lung Cancer Foundation of America (LCFA) was established by two lung cancer survivors and a lung cancer widow. Despite their varied backgrounds, they all arrived at the same realization - the poor survival rate for lung cancer is a direct result of the lack of funding for lung cancer research. Working with many of the top lung cancer researchers and clinicians in the country, they have observed how these experts attempt to diligently unlock the secrets unique to lung cancer. LCFA’s mission is the dramatic improvement in survivorship of lung cancer patients through the funding of transformative science, with the ultimate goal of curing the disease. To accomplish this, LCFA works to raise both the funds and the national profile of lung cancer in order to substantially increase support for innovative and groundbreaking research efforts. http://www.lcfamerica.org.
American Lung Association
The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease. As part of its strategic imperative to defeat lung cancer, the Lung Association created LUNG FORCE, a new national movement to unite women against lung cancer, the #1 cancer killer of women. LUNG FORCE has three priorities: 1) Make lung cancer a cause that people care about - and act on; 2) Raise critical funds for lung cancer research, and 3) Educate and empower patients and healthcare providers. The Lung Association is proud to partner with Lung-MAP under its LUNG FORCE initiative to increase awareness of and access to clinical trials as a key piece of empowering patients to be their own healthcare advocates. Find out more by visiting LUNGFORCE.org or www.lung.org, or by calling 1-800-LUNG-USA (1-800-586-4872).
American Cancer Society
The American Cancer Society is a global grassroots force of more than three million volunteers saving lives and fighting for every birthday threatened by every cancer in every community. As the largest voluntary health organization, the Society's efforts have contributed to a 20 percent decline in cancer death rates in the U.S. since 1991, and a 50 percent drop in smoking rates. Thanks in part to our progress nearly 14 million Americans who have had cancer and countless more who have avoided it will celebrate more birthdays this year. As we mark our 100th birthday in 2013, we're determined to finish the fight against cancer. We're finding cures as the nation’s largest private, not-for-profit investor in cancer research, ensuring people facing cancer have the help they need and continuing the fight for access to quality health care, lifesaving screenings, clean air, and more. For more information, to get help, or to join the fight, call us anytime, day or night, at 1-800-227-2345 or visit www.cancer.org/fight.
Uniting Against Lung Cancer
Uniting Against Lung Cancer is dedicated to funding innovative research and raising awareness to find a cure for lung cancer. With Partners across the country, Uniting Against Lung Cancer has funded over $11.5 million in lung cancer research to the nation's leading cancer centers and hospitals, resulting in significant advances in treatment for lung cancer patients. For more information, please visit www.UnitingAgainstLungCancer.org.
Design Phase Support
Successfully designing and establishing the infrastructure for a trial as large and complex as Lung-MAP required the expenditure of significant time, effort, and resources from many partners over many months. We are particularly grateful to the following organizations who provided financial support for the design phase of the trial. It could not have been launched without them: